We are thrilled to present the 2023 inaugural Impact Report for the Children’s Cancer Therapy Development Institute (cc-TDI), a testament to our joint commitment to advancing childhood cancer research and improving outcomes for patients worldwide.
Thanks to your incredible support, researchers:
- Continued to advance basic science discovery by understanding fundamental mechanisms of childhood cancers, unlocking crucial insights into novel therapeutic targets and pathways, and laying the groundwork for transformative treatments
- Worked to de-risk clinical trial investments by leveraging cutting-edge techniques and innovative approaches to accelerate the translation of promising potential therapies
- Furthered our engineering-forward initiatives using AI for computational drug design with national and international collaborators in an effort to increase the speed and effectiveness of drug discovery
- Continued to foster the next generation of scientific leaders through mentorship programs and hands-on experience and cultivating a vibrant community of passionate research advocates
- And as always, we remain committed to supporting families, recognizing the pivotal role they have in the fight against childhood cancer
As we reflect on the achievements of 2023, we are deeply grateful for your partnership in our mission. Your support allowed cc-TDI researchers to make significant strides in 2023 and this inaugural impact report encapsulates the progress we’ve made in our pursuit of innovative solutions to combat childhood cancer.
This month marks one year in our new laboratory and we encourage you to join us virtually as we celebrate this milestone on Monday, May 13th, 2024 at 4:00 PM PST. Meet our research team, receive a virtual lab tour, hear first-hand about exciting research projects on the horizon – and so much more! Click HERE to RSVP.
Thank you for partnering with us as we aim to make childhood cancer universally survivable. We look forward to new and exciting discoveries in 2024 and beyond!
